U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562841) titled 'Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy' on April 24.
Brief Summary: Advanced melanoma is a highly aggressive malignancy that frequently exhibits resistance to conventional radiotherapy and single-agent immunotherapy. This study aims to evaluate the safety and tolerability of Au-TMP, an innovative nanoparticle platform, in patients with advanced melanoma. This single-arm, open-label, Phase Ia clinical trial utilizes a dose-escalation design, where participants receive a single intratumoral injection of Au-TMP followed by sequential radiotherapy and Toripalimab (anti-PD-1) treatment. This trial aims at asse...